Moderna News - August 25, 2026
Moderna Upgraded by Wolfe Research, Citing Phase 3 Cancer Vaccine Success
Wolfe Research upgraded Moderna from Underperform to Peer Perform. The rating change follows a successful Phase 3 trial for intismeran, a personalized cancer...
🟢 Moderna is trading 11% up today after positive Phase 3 melanoma-vaccine results
Moderna is trading at $153.71 (+10.67%) as investors extend the sharp repricing after its August 19 Phase 3 melanoma-vaccine results with Merck showed reduced...
🟢 Moderna is trading 6% up today as investors refocus on positive melanoma vaccine results
Moderna is trading 5.67% up at $146.77 after renewed investor attention to positive Phase 3 results for its personalized melanoma vaccine. - Moderna and Merck...